BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 28, 2015
View Archived Issues
Dose-finding data from phase I study of AZD-8186 reported
Read More
Incyte presents the novel BET inhibitor INCB-054329
Read More
Generex announces buccal cannabis agreements
Read More
Pernix closes acquisition of Zohydro ER franchise
Read More
Novartis reviews key events of first quarter 2015
Read More
Scientists disclose new data on the effects of lorcaserin
Read More
Basmisanil has effects on EEG in subjects with Down syndrome
Read More
Re-analysis of phase II/III data support small-molecule drug CF-101 for psoriasis
Read More
Teva Pharmaceuticals relinquishes anticancer agent custirsen
Read More
First NDA submission for Merrimack Pharmaceuticals
Read More
AbbVie recalls milestones of first quarter 2015
Read More
SignalRx Pharmaceuticals discloses dual PI3K/BRD4 inhibitors
Read More
Columbia University presents SLC7A11 inhibitors
Read More
Infinity Pharmaceuticals discloses PI3K inhibitors
Read More
Cancer Research Technology patents HSF-1 inhibitors
Read More
CS Therapeutics introduces new ALK inhibitors
Read More
Mallinckrodt patents new berbines for cancer
Read More
Preclinical activity of BLU-554 prompts plans for a phase I trial
Read More
European orphan drug designation for VentiRx's motolimod in ovarian cancer
Read More
CPI-431-32 as a potential new treatment for HBV/HCV and HIV-1 coinfection
Read More
Dabrafenib and trametinib application filed in Japan for BRAF V600-mutated malignant melanoma
Read More
EMA classifies NeoStem's NBS-20 as advanced therapeutic medicinal product
Read More
Recruitment initiated in phase II trial of CicloMulsion for acute kidney injury
Read More
Daiichi Sankyo's edoxaban recommended for stroke prevention in Europe
Read More
Astellas launches Cresemba in the U.S. for invasive aspergillosis and invasive mucormycosis
Read More
DSMB recommends continuation of phase III trial of zoptarelin doxorubicin in endometrial cancer
Read More